Tony Berberabe, MPH

The non-invasive liquid biopsy, if validated, could lead to the development of a personalized selection tool in men with advanced prostate cancer.

When compared with the National Comprehensive Cancer Network (NCCN) breast cancer guidelines, the corresponding prostate cancer guidelines fall short in one distinct characteristic—the lack of a molecular test in tissue-based platforms at this point in time.

Recent trends suggest a shift away from radiation therapy and more toward radical prostatectomy for patients with high-risk prostate cancer.

The prognosis for patients with bladder cancer who have progressed after platinum-based chemotherapy is poor, but the results of a phase II study involving an immunotherapy hold promise.

A test called the Stockholm 3 (STHLM3) has been shown to detect aggressive prostate cancer cancer earlier, reduce the number of false positives, and decrease the number of unnecessary biopsies.

Findings from a subgroup of patients enrolled in a phase II study assessing the dendritic vaccine ICT-107 for patients with HLA-A2+ glioblastoma multiforme merit further exploration in a phase III study.

With the emergence of the novel treatments abiraterone acetate (Zytiga) and enzalutamide (Xtandi), urology groups are beginning to offer in-office dispensing to their metastatic castration-resistant prostate cancer patients.

Thomas E. Keane, MD, ChB, discussed combination approaches in treatment-resistant mCRPC at the 2015 LUGPA Annual Meeting.

Independent urology practices are at a crossroads as they face substantial Medicare payment change, shifts in physician employment and autonomy, and cutting edge developments in clinical care.

Proinflammatory cytokines were elevated in patients with melanoma undergoing the combination treatment of radiation therapy and the systemic anti–CTLA-4 immunotherapy, ipilimumab.

The FDA has issued a de novo clearance for a minimally invasive high-intensity focused ultrasound for prostate tissue ablation called Sonablate 450 and marketed by SonaCare Medical, LLC.

Patients with renal cell carcinoma have better outcomes when undergoing nephron-sparing surgery rather than radical nephrectomy.

With the advancement of radium-223 comes questions and controversy regarding optimal treatment sequencing, combination therapy, and appropriate patient selection.

In the urologic oncology field, urologists can play an important role in successful comprehensive care by incorporating palliative care in their treatment regimens.

Concomitant therapy with docetaxel and androgen deprivation therapy initiated at the start of treatment for men with metastatic prostate cancer resulted in an increased survival of 13.6 months compared with men who received ADT alone.

New diagnoses of prostate cancer cases declined nearly 30% after the United States Preventive Services Task Force recommended against routine prostate-specific antigen screening for men.

Urologists who are in solo practice or not affiliated with a medical school may overuse primary gonadotropin-releasing hormone for men with localized prostate cancer.

Men with intermediate- or high-risk prostate cancer experienced higher survival rates when given increased radiation doses than men with low-risk disease.

Patients who were taking statins while also undergoing androgen deprivation therapy may experience a reduction in all-cause and prostate cancer-specific deaths.

Charles J. Ryan, MD, discusses the final survival data for pre-chemotherapy use of abiraterone from the COUGAR-AA-302 study, which demonstrated a median of 35 months for men with castration resistant prostate cancer.

There are many processes for a urology practice to consider when partnering with a specialty pharmacy, including time and capital investments.

Using an allograft made up of dehydrated human amnion/chorion membrane wrapped around the neurovascular bundle (NVB) during nerve-sparing robot-assisted radical prostatectomy improved continence and potency postsurgery, according to results of a small study.

Interest is high among urologists and medical oncologists with "the explosion of checkpoint blockade inhibition studies" that initially made inroads in melanoma and non-small cell lung cancer, but is also gaining traction in bladder cancer.

Two urine biomarkers, aquaporin 1 and perilipin 2, could be the key to the development of a simple urine test that leads to the detection of asymptomatic, early-stage kidney cancer.

Treatment with an adjuvant combination of docetaxel, androgen deprivation therapy (ADT), and radiation therapy (RT) improved 4-year overall survival rates in patients with high-risk localized prostate cancer, when compared with ADT plus RT alone.

After weeks of deliberations, the final votes have been cast and the winners of the 2015 Giants of Cancer Care® can now be revealed.

The growing use of genetic biomarker tests to screen, monitor, diagnose, and treat patients with cancer has the potential to improve outcomes and reduce costs, but payment systems for covering and reimbursing for these tests have fallen behind the times.

The combination of multiparametric MRI with a fusion-guided biopsy (MRI plus ultrasound) was more effective at detecting aggressive prostate cancer compared with either procedure alone.

Sexual function scores were better for patients who had a robotic compared with open surgery for prostate cancer; however, comparative results for urinary function were not conclusive.

Since the USPSTF guideline on PSA screening the overall rate of PSA testing decreased by 50% among primary care physicians at Oregon Health & Science University.